Deprivation of arginine by recombinant human arginase in prostate cancer cells

BACKGROUND: Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of orni...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsueh, Eddy C, Knebel, Stephanie M, Lo, Wai-Hung, Leung, Yun-Chung, Cheng, Paul Ning-Man, Hsueh, Chung-Tsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403903/
https://www.ncbi.nlm.nih.gov/pubmed/22546217
http://dx.doi.org/10.1186/1756-8722-5-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403903/
https://www.ncbi.nlm.nih.gov/pubmed/22546217
http://dx.doi.org/10.1186/1756-8722-5-17

Ejemplares similares